Raks Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.75 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.62 Cr
as on 16-11-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 16.76 Cr
as on 16-11-2024
- Revenue 67.61%
(FY 2023)
- Profit 420.33%
(FY 2023)
- Ebitda 183.99%
(FY 2023)
- Net Worth 119.32%
(FY 2023)
- Total Assets 17.76%
(FY 2023)
About Raks Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.75 Cr and a paid-up capital of Rs 1.62 Cr.
The company has closed loans amounting to ₹16.76 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Suresh Patel, Sandeep Raktate, Rajeev Midha, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233GJ2008PTC068526
- Company No.
068526
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Oct 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Raks Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Raktate  | Director | 27-May-2024 | Current |
| Rajeev Midha | Director | 25-Jan-2019 | Current |
| Suresh Patel | Director | 30-Jul-2010 | Current |
| Rahul Maitra | Director | 27-May-2024 | Current |
Financial Performance and Corporate Structure Insights of Raks Pharma.
Raks Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 67.61% increase. The company also saw a substantial improvement in profitability, with a 420.33% increase in profit. The company's net worth Soared by an impressive increase of 119.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raks Pharma?
In 2023, Raks Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Amneal Oncology Private LimitedActive 26 years 1 monthSuresh Patel and Rajeev Midha are mutual person
Amneal Healthcare Private LimitedActive 3 years 6 monthsSuresh Patel, Sandeep Raktate and 2 more are mutual person
Amneal Pharmaceuticals Private LimitedActive 18 years 8 monthsSuresh Patel and Rajeev Midha are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 10 Feb 2010 | ₹16.76 Cr | Satisfied |
How Many Employees Work at Raks Pharma?
Raks Pharma has a workforce of 467 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raks Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raks Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
